Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human serum albumin + growth hormone fusion protein
- Development stage
- Unknown
- Lead developer
- Zhejiang Unogene Bioengineering
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant human serum albumin + growth hormone fusion protein (rHSA-GH) is a long-acting biologic fusion protein developed by Zhejiang Younuo Gold Bioengineering for the treatment of pediatric growth hormone deficiency. The drug consists of human growth hormone (hGH), a 191-amino acid polypeptide, genetically fused to recombinant human serum albumin (rHSA). This fusion leverages the long circulatory half-life of albumin to extend the duration of action of the growth hormone, thereby reducing the required dosing frequency from daily to weekly or less frequent subcutaneous injections. rHSA-GH acts as an agonist at the growth hormone receptor (GHR), stimulating the production of insulin-like growth factor 1 (IGF-1) and promoting linear growth and metabolic regulation. It has been evaluated in Phase 1 clinical trials in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.
- Other names
- recombinant human serum albumin–growth hormone fusion protein
02
Targets
GHR (Growth hormone receptor)ALB (Human serum albumin)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on recombinant human serum albumin + growth hormone fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human serum albumin + growth hormone fusion protein.